Activity Overview
This educational activity is an archive of the live conference held from February 26, 2026, through February 28, 2026.
Target Audience
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Evaluate recent clinical trial results on approved and emerging therapeutic approaches for patients with hematologic disorders
- Interpret the latest guidelines and evidence for the use of biomarker-driven strategies to stratify risk and select appropriate therapies for patients with hematologic disorders
André H. Goy, MD
Vice President Physician in Chief Oncology
Chairman & Chief Physician Officer - John
Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack
Meridian School of Medicine
Professor of Medicine – Georgetown University
Hackensack, NJ
Lorenzo Falchi, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell Medical College
New York, NY
Christopher Flowers, MD, MS, FASCO
Division Head, Division of Cancer Medicine
Chair, Professor, Department of
Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams
Distinguished University
Chair in Cancer Medicine
The University of Texas MD Anderson Cancer
Center
Houston, TX
Lori A. Leslie, MD
Associate Professor of Medicine
Hackensack Meridian School of Medicine
Attending Physician, Lymphoma Division
Director, Indolent Lymphoma and CLL Research
Programs
John Theurer Cancer Center
Hackensack, NJ
Please click here to view disclosures for faculty and the staff of Physicians’ Education Resource®.